SCYNEXIS, Inc. (SCYX)
- Previous Close
2.0400 - Open
2.0300 - Bid 1.9000 x 400
- Ask 2.0000 x 400
- Day's Range
1.8400 - 2.0500 - 52 Week Range
1.3500 - 3.8700 - Volume
160,129 - Avg. Volume
208,314 - Market Cap (intraday)
73.671M - Beta (5Y Monthly) --
- PE Ratio (TTM)
0.92 - EPS (TTM)
2.1100 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.88
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
www.scynexis.com29
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SCYX
Performance Overview: SCYX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCYX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCYX
Valuation Measures
Market Cap
77.07M
Enterprise Value
-330.22k
Trailing P/E
0.97
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.71
Price/Book (mrq)
1.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
72.18%
Return on Assets (ttm)
48.96%
Return on Equity (ttm)
458.59%
Revenue (ttm)
140.38M
Net Income Avi to Common (ttm)
101.33M
Diluted EPS (ttm)
2.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
80.24M
Total Debt/Equity (mrq)
20.56%
Levered Free Cash Flow (ttm)
36.62M
Research Analysis: SCYX
Company Insights: SCYX
SCYX does not have Company Insights